Related Experiment Video
Updated: May 20, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Cryptogenic stroke and patent foramen ovale
Insights
For cryptogenic stroke patients with a patent foramen ovale, both medical therapy and device closure are effective stroke prevention options. The best choice depends on individual patient risks, benefits, and adherence.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Cryptogenic stroke affects patients with a patent foramen ovale (PFO).
- PFOs are a potential source of paradoxical embolism causing stroke.
- Current stroke prevention strategies include medical therapy and device closure.
Purpose of the Study:
- To compare the efficacy of medical therapy versus percutaneous device closure for stroke prevention in patients with cryptogenic stroke and PFO.
- To inform clinical decision-making regarding stroke prevention strategies.
Main Methods:
- Review of the only completed randomized controlled trial comparing medical therapy and PFO device closure.
- Analysis of patient outcomes based on treatment received.
Main Results:
- No significant difference in outcomes was observed between medical therapy and percutaneous device closure.
- Both treatment strategies are considered viable options for stroke prevention in this patient population.
Conclusions:
- The choice between medical therapy and PFO device closure should be individualized.
- Consideration of patient-specific risks, benefits, and anticipated adherence is crucial.
- Clinical trial participation remains an alternative option for eligible patients.
Abstract:
In patients with cryptogenic stroke and patent foramen ovale, options for stroke prevention include medical therapy (antiplatelet therapy or anticoagulation) and percutaneous device closure. In the only completed randomized controlled trial comparing medical therapy and percutaneous device closure, there was no difference in outcome between the two forms of treatment, and both are viable options for stroke prevention. The choice of therapy is made after careful weighing of potential risks and benefits associated with each form of therapy based on the limited evidence to date and the anticipated patient adherence with the planned treatment. Participation in a clinical trial is a third option for these patients.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Stroke: Introduction and Types
Hemorrhagic Stroke l: Introduction
